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ABSTRACT 
 
Machado Joseph disease, or spinocerebellar ataxia type 3, is a hereditary neurodegenerative 
disorder with severe clinical features, being the most common autossomal dominant 
spinocerebellar ataxia worldwide. This disease is caused by the expansion of the CAG repeat 
region in the ATXN3/MJD1 gene, which translates into an expanded polyglutamine tract within 
the affected protein ataxin-3. Mutant ataxin-3 becomes prone to misfolding, accumulating as 
nuclear and intracellular inclusions and acquires toxic properties, which lead to neuronal 
dysfunction and cell death. 
The lysosomal-macroautophagy pathway (here termed autophagy) is a major clearance 
pathway for the degradation of dysfunctional proteins and organelles and also essential in the 
removal of aggregate-prone intracytosolic proteins, such as mutant ataxin-3. Recently, our 
group provided evidence of the implication of autophagy in the accumulation of mutant ataxin-3 
aggregates and neurodegeneration in Machado-Joseph disease, supporting the idea that 
modulation of autophagy might be a suitable strategy to mitigate the disease. The current 
pharmacological strategy for upregulating autophagy through inhibition of the mammalian 
target of rapamycin (mTor) may lead to complications associated to rapamycin 
immunosuppressant activity. Therefore, other pathways should be investigated particularly the 
mTor-independent autophagy induction. Recent evidence suggests that carbamazepine (CBZ), 
an anticonvulsant and mood-stabilizing drug, signals through phosphoinositol pathway, 
lowering inositol and IP3 levels and presumably enhancing the autophagy and the clearance of 
aggregate-prone proteins. Given these evidences the main goal of this study was to investigate 
the beneficial effects of CBZ in the alleviation of Machado Joseph disease, mediated by its 
autophagy-enhancing ability. 
For this purpose we used a neuroblastoma cellular model, and two animal models, 
respectively a lentiviral-based MJD mouse model and a transgenic mouse model of disease. In 
neuroblastoma cells, we found that CBZ mediates a decrease of mutant ataxin-3 levels, by 
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enhancing autophagy, which was detected by increase of a) LC3-positive autophagic vesicles, b) 
the ratio of LC3II/LC3I protein levels and c) mRNA expression of LC3. In in vivo experiments, 
using the lentiviral-based model, treatment with CBZ resulted in an improvement of 
neuropathology indicated by a decrease of the number of mutant ataxin-3 inclusions and of the 
volume of the brain region depleted of the darpp-32 marker Moreover, evaluation of the effects 
of CBZ in transgenic mice, revealed a decrease of both aggregated and soluble mutant protein, 
accompanied by increased levels of mRNA for the autophagy marker LC3 in treated animals. 
To examine the effects of long-term use of CBZ on motor coordination and activity profile of 
transgenic mice behavioural tests were performed, using the rotarod and activity box tests. 
Treated mice presented better performance relative to control mice, travelled increased 
distances, spending less time resting and more time moving fast. 
Altogether these results suggest that CBZ ability to activate autophagy might be a suitable 
therapeutic approach to mitigate Machado-Joseph disease and potentially to other diseases 
characterized by misfolding and toxicity of aggregate-prone proteins. 
 
Keywords: MJD; Atx3MUT; CBZ; autophagy; mTor independent pathway 
 
 
RESUMO 
 
A doença de Machado Joseph ou ataxia espinocerebelosa do tipo 3, é uma doença 
neurodegenerativa hereditária com manifestações clínicas severas, sendo a ataxia 
espinocerebelosa dominante autossómica mais comum em todo o mundo. Esta doença é causada 
por uma repetição excessiva do trinucleótido CAG no gene MJD1/ATXN3, que se traduz numa 
cadeia de glutaminas expandida na proteína afetada, ataxina-3. Devido a esta mutação, a ataxina 
3 mutante toma conformações alteradas e adquire propriedades tóxicas, que levam a 
acumulação de inclusões nucleares e citoplasmáticas, disfunção neuronal e a morte celular. 
A via lisosomal da autofagia (aqui designada de autofagia) é um importante mecanismo de 
degradação de proteínas e organelos disfuncionais, e também fundamental na eliminação de 
proteínas insolúveis com tendência para agregar; como é característico da ataxina-3 mutada 
nesta doença. Recentemente o nossos grupo apresentou evidências da implicação da autofagia 
na doença de Machado Joseph, reforçando a ideia que a modulação da autofagia poderá ser uma 
estratégia viável para mitigar a doença. A estratégia farmacológica de ativação da autofagia 
recorrendo ao uso da rapamicina e seus análogos, que têm a capacidade de inibir o complexo 
mTor (mammalian target of rapamycin) tem contra-indicações para tratamentos a longo prazo 
devido à sua actividade imunossupressora. Desta forma, impõe-se o estudo de outras vias cuja 
ativação da autofagia seja independente do complexo mTor. Evidências recentes sugerem que a 
carbamazepina (CBZ), um anticonvulsivo e estabilizador de humor, atua na via de sinalização 
do fosfoinositol, diminuindo os níveis de inositol e IP3, o que presumivelmente leva à ativação 
da autofagia e à degradação de proteínas agregadas. Tendo em conta estas evidências, o 
principal objetivo deste estudo foi investigar os potenciais efeitos benéficos da carbamazepina 
na atenuação da doença de Machado Joseph. 
Nesse sentido, recorremos a modelos celulares da doença, bem como ao modelo lentiviral e 
transgénico no roedor. Nas células de neuroblastoma verificámos que a carbamazepina levou a 
uma diminuição dos níveis da proteína mutada mediada por autofagia, o que foi detetado pelo 
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aumento do número de vesículas positivas para o marcador de autofagia LC3, do rácio de 
LC3II/LC3I e pelos níveis aumentados de expressão de LC3. 
As experiências in vivo, usando o modelo lentiviral, mostraram que o tratamento com CBZ 
resultou numa melhoria da neuropatologia indicada pela diminuição do número de inclusões de 
ataxina-3 mutante e de perda de volume do marcador DARPP-32. Para além disso, a avaliação 
dos efeitos da CBZ em murganhos transgénicos revelou uma diminuição da proteína mutante 
agregada e solúvel, acompanhada por um aumento da expressão de LC3 nos animais tratados. 
De forma a avaliar o efeito a longo prazo do uso da CBZ na coordenação motora e perfil de 
movimento e atividade foram realizados testes de comportamento recorrendo à roda rotativa e 
caixa de atividade. Os animais tratados apresentaram melhor performance relativamente aos 
controlos, percorrendo distâncias superiores, permanecendo menos tempo imóveis e mais tempo 
em movimento rápido. 
Em suma, estes resultados sugerem que a capacidade da CBZ em ativar a autofagia poderá 
ser uma abordagem terapêutica viável no tratamento da doença de Machado-Joseph e 
potencialmente de outras doenças caracterizadas pela acumulação de proteínas agregadas. 
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1.1. Triplet Repeats Disease 
Several human neurological disorders have been found to be associated with a type of 
genetic mutation: the expansion of trinucleotide repeats (Fu et al., 1991; La Spada et al., 1991). 
These repeats show moderate levels of length variation within the normal population. However, 
in disease conditions, the repeat expands beyond the normal range, altering the biological 
function of the gene. The unstable properties of triplet repeat DNA sequences explain the non-
Mendelian inheritance patterns, as well as the increase in severity and the decrease in the age at 
onset of a disease in subsequent generations.  
The expansion of triplet repeat may be found in coding regions, as in the spinal and bulbar 
muscular atrophy (SBMA) and huntington’s disease (HD) or in non-conding regions (introns, 
5’UTR, 3’UTR), as is the case of Fragile X syndrome (Tsuji, 1997). The mutation in 
noncoding-repeat regions leads to a loss of function of the respective proteins or, in some cases, 
an acquired function of a toxic triplet repeat transcript, which accounts the different mechanisms 
of pathology. Exonic CAG repeat expansions translate into a long polyglutamine tract, 
conferring a toxic function to the protein (Cummings and Zoghbi, 2000). This class of disorders 
is called as polyglutamine diseases. 
 
1.1.1. Polyglutamine diseases 
Polyglutamine diseases consist of a group of neurodegenerative disorders, including HD, 
dentatorubral-pollidoluysian atrophy (DRPLA), Kennedy’s disease or spinal and bulbal 
muscular atrophy (SBMA, X-linked recessive disorder) and six forms of spinocerebellar ataxias 
(SCAs) (Orr and Zoghbi, 2007; Havel et al., 2009; Wilburn et al., 2011) (see table 1). Despite 
the wide range of neurological, psychiatric and motor symptoms present in these conditions, all 
disorders are progressive, typically striking in midlife and causing increasing neuronal 
dysfunction and eventual neuronal loss 10–20 years after onset of symptoms (Zoghbi and Orr, 
2000; Gatchel and Zoghbi, 2005). 
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 Table 1 Polyglutamine diseases 
HD,  Huntington’s  disease;  DRPLA,  dentatorubral-pallidoluysian  atrophy;  SBMA, spinal  and  bulbar  muscular  
atrophy;  SCA,  spinocerebellar  ataxia; MJD Machado-Joseph disease; CACNA1A,  calcium  channel,  voltage  
dependent,  P/Q  type,  a1A  subunit;  TBP,  TATA  box  binding  protein. 
 
An important common feature to all polyQ diseases is the negative correlation between the 
age of onset and the number of CAG repeats, leading to an earlier development of the disease 
(Maciel et al., 1995; Maruyama et al., 1995; Ranum et al., 1995; Zoghbi and Orr, 2000; Riess et 
al., 2008). 
The genetic similarities among all these diseases could indicate a possible common 
mechanism of pathogenesis, caused by the toxic properties of the polyglutamine tract. 
Several mechanisms of pathogenesis have been proposed (Fig.1.1). In many polyglutamine 
diseases, such as HD, SBMA and SCA3/MJD, the pathogenesis is associated to proteolityc 
Disease Protein CAG repeat Inclusions Brain regions most affected 
Normal      Pathogenic 
HD Huntingtin 6-34 36-121 Nuclear and 
cytoplasmatic 
Striatum, cerebral cortex 
SMBA Androgen 
receptor 
9-36 38-62 Nuclear and 
cytoplasmatic 
Anterior horn and bulbar 
neurons, dorsal root ganglia 
DRLPA Atrophin 1 7-34 49-88 Nuclear Cerebellum, cerebral cortex, 
basal ganglia, Luys body 
SCA1 Ataxin 1 6-39 40-82 Nuclear Cerebellar Purkinje cells, 
dentate nucleus, brainstem 
SCA2 Ataxin 2 15-24 32-200 Nuclear Cerebellar Purkinje cells, brain 
stem, frontotemporal lobes 
SCA3/
MJD 
Ataxin 3 13-36 61-84 Nuclear Cerebellar dentate neurons, 
basal ganglia, brain stem, spinal 
cord 
SCA6 CACNA1 A 4-20 20-29 Citoplasmatic Cerebellar Purkinje cells, 
dentate nucleus, inferior olive 
SCA7 Ataxin-7 4-35 37-306 nuclear Cerebellum, brain stem, macula, 
visual cortex 
SCA17 TBP 25-42 47-63 nuclear Cerebelllar Purkinje cells, 
inferior olive 
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cleavage that generates a toxic fragment. The expanded polyglutamine tract within a target 
protein facilitates transition to a novel, toxic conformation, causing alterations at different 
levels. Toxicity may be caused by the peptide as a monomer or it associated form: oligomers. 
The oligomers can assemble into larger aggregated species and eventually are deposited in 
intracellular inclusions. Proteolytic cleavage of full-length protein into toxic cleavage fragment 
may also contribute to this process. 
The main toxic effects of the pathological protein include transcriptional changes, caused by 
interactions of the expanded protein with transcription factors; proteotoxic stress as a result of 
the disruption of the quality control systems of the cell and metabolism and mitochondrial 
dysfunction (Shao and Diamond, 2007) (Fig.1.1).  
The majority of polyglutamine disorders are spinocerebellar ataxias. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Mechanisms of pathogenesis of polyglutamine diseases(Gatchel and Zoghbi, 2005). 
*mutant polyglutamine protein 
 
 
 
 
* 
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1.1.2. Autossomal dominant spinocerebellar ataxias  
 
SCAs are a heterogeneous group of neurologic disorders characterized by variable degrees of 
degeneration of the cerebellum, spinal tracts, and brain stem. The autosomal dominant 
spinocerebellar ataxias present progressive gait and limb ataxia as a core clinical feature of 
SCAs—in most cases the predominant, disabling feature of disease— but the ataxia is usually 
accompanied by signs and symptoms that reflect damage beyond the cerebellum and its afferent 
and efferent pathways (Paulson, 2007). The disease onset is usually between 30 and 50 years of 
age, progressively evolving to a fatal state (Zoghbi, 2000; Taroni and DiDonato, 2004; Duenas 
et al., 2006; Carlson et al., 2009).  
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1.2. Spinocerebellar ataxia type 3/Machado Joseph-disease 
 
SCA3 or MJD is a clinically and genetically heterogeneous neurodegenerative disorder 
which leads to progressive cerebellar ataxia (Schols et al., 1995). This neurodegenerative 
disease was first described among Portuguese immigrants living in New England, United States 
of America (U.S.A) as an autosomal dominant form of ataxia in the descendants of William 
Machado (Nakano et al., 1972). A few years later, other cases in Thomas and Joseph families of 
Portuguese immigrants were described in the U.S.A. (Woods and Schaumburg, 1972; 
Rosenberg et al., 1976). These reports led to different designations: Machado disease; Nigro-
spino-dentatal-degeneration with nuclear ophthalmoplegia (Woods and Schaumburg, 1972), 
Joseph disease (Rosenberg et al., 1976) and Azorean disease (Romanul et al., 1977). Later on, 
Lima and Coutinho proposed the name of Machado-Joseph disease for the previously described 
clinical entities (1980). An autosomal dominant ataxia called spinocerebellar ataxia type 3 
(SCA3) was also described, but after genetic studies, by identification of the MJD1 gene, it was 
shown that both correspond to the same disease (Kawaguchi et al., 1994; Stevanin et al., 1994; 
Cancel et al., 1995; Twist et al., 1995). 
Presently, MJD is considered the most common form of SCA worldwide (Schols et al., 
2004). It presents a large geographic distribution with higher frequency in countries such as 
Brazil and Portugal, which reaches highest values in the islands of the Azores (Lima et al., 
1997), China and Germany (Schols et al., 1997; Jardim et al., 2001; van de Warrenburg et al., 
2002; Jiang et al., 2005; Vale et al., 2010). 
 
1.2.1. Clinical symptoms  
MJD is a neurodegenerative disorder characterized by a wide range of clinical manifestations 
involving predominantly the cerebellar, pyramidal, extrapyramidal, motor neuron and 
oculomotor systems (Bettencourt and Lima, 2011). The phenotype is one of the most variable 
(Rosenberg et al., 1976) among SCAs; typical signs include ataxia, progressive external 
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ophthalmoplegia, pyramidal and extra pyramidal signs such as dystonia with rigidity, distal 
muscular atrophies, facial and lingual fasciculation, nystagmus, eyelid retraction, as well as 
bulging eyes. Sleep disturbance are also common in SCA3 and mostly derive from restless legs 
syndrome and periodic leg movements in sleep responding to dopaminergic stimulation (Lima 
and Coutinho, 1980; Rosenberg, 1992; Sudarsky and Coutinho, 1995; Schols et al., 1998). 
Disease manifestations usually start during adulthood, with a mean age at onset of 37.4 
years. The average survival time after onset is 20 years (Sequeiros and Coutinho, 1993). The 
wide of clinical features of MJD led to classification in various subtypes of disease (Cancel et 
al., 1995; Maciel et al., 1995; Durr et al., 1996; Jardim et al., 2001).   
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1.2.2. Neuropathology 
The neuropathology of MJD consists of neuronal loss in many regions of the brain, 
specifically in the basal ganglia, thalamus, midbrain, pons, medulla oblongata and cerebellum 
(Fig. 1.2). In addition, there is loss of pontine neurons, neurons of the substantia nigra, anterior 
horn cells, and Clarke’s column in the spinal cord, as well as neurons in many cranial motor 
nuclei and posterior root ganglia. Structures such as the cerebral and cerebellar cortex and 
inferior olives are relatively spared (Rosenberg et al., 1976; Coutinho and Andrade, 1978; 
Coutinho et al., 1982; Sakai et al., 1983; Kanda et al., 1989). 
A hallmark of neurodegeneration in brains of patients with MJD is the presence of neuronal 
intranuclear inclusions (NIIs). These inclusions result from the nuclear accumulation of 
misfolded and toxic forms of mutant polyQ proteins (Paulson et al., 1997; Schmidt et al., 1998). 
NIIs are spherical and eosinophilic aggregates, varying size from 1 to 4 µm (Yamada et al., 
2008). It is known that these NIIs contain numerous other proteins such as proteasome subunits, 
ubiquitin (Chai et al., 1999), and several transcription factors (Schaffar et al., 2004). Therefore, 
neuronal intranuclear inclusions might be linked to the pathogenesis of polyQ diseases through 
mechanisms such as the impediment of transcription due to the sequestration of transcriptional 
activators (McCampbell et al., 2000; Chai et al., 2002) and the disturbance of the quality control 
systems, due to recruitment of proteasome components and chaperones (Paulson et al., 1997; 
Chai et al., 1999; Chai et al., 1999; Warrick et al., 1999; Ferrigno and Silver, 2000; Muchowski 
et al., 2000; Schmidt et al., 2002), causing cellular dysfunction. 
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Figure 1.2. Distribution of neuronal loss in the brain of patients with Machado Joseph disease. 
Diagrammatic representation of midsagittal sections through the cerebrum, cerebellum and brainstem of 
the human brain. The degree of neuronal loss in the cerebral cortex, basal forebrain, thalamus, cerebellum 
and brainstem is indicated by red (severe) or light red (marked) (Seidel et al., 2012). 
 
1.2.3. MJD1/ATXN3 gene 
The disease locus was first mapped in the long arm of chromosome 14q32.1 (Takiyama et 
al., 1993) and in 1994 the MJD1/ATXN3 gene was identified (Kawaguchi et al., 1994). A few 
years later, the genomic structure of the MJD gene was described. The MJD1 gene was found to 
span 48,240 bp and to contain 11exons, with the CAG tract located at the exon 10. Transcripts 
ubiquitously expressed in human tissues with different sizes- 1.4, 1.8, 4.5, and 7.5kb, probably 
resulting from differential splicing (exon 10 or 11) and polyadenylation (exon 11) were also 
detected (Ichikawa et al., 2001). Recently two novel exons were described for the MJD1 gene 
by Bettencourt and collaborators. Fifty-six alternative splicing variants, generated by four types 
of splicing events, were observed, of which 50 of those transcripts were not previously 
described and 26 were MJD-specific (Bettencourt et al., 2010). 
The normal MJD1 gene encodes a polyQ-containing protein named ataxin-3 (atx3); in 
pathologic conditions the overrepetition of the CAG trinucleotide translates into an expanded 
polyglutamine tract at the C-terminus of ataxin-3 (Kawaguchi et al., 1994; Durr et al., 1996). 
The highly polymorphic CAG repeats are unstable and selectively expanded in MJD patients. 
The wild-type alleles of MJD1 range from 12 to 44 CAG repeats whereas MJD patients alleles 
range from 52 up to 87 repeats. Although rare, there is an intermediate size where alleles have 
between 45 and 51 CAG repeats (Kawaguchi et al., 1994; Cancel et al., 1995; Maciel et al., 
1995; Maciel et al., 2001; Padiath et al., 2005). 
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1.2.4. Ataxin-3 protein 
1.2.4.1. Expression and subcellular localization 
MJD1 gene encodes ataxin-3, an intracellular protein of unclear physiological role with a 
predicted molecular weight of 42 kDa, depending on the number of CAG repeats (Kawaguchi et 
al., 1994). Wild-type ataxin-3, as well as the mutant ataxin-3, is expressed ubiquitously in 
different human tissues and cell types (Paulson et al., 1997; Wang et al., 1997; Trottier et al., 
1998; Ichikawa et al., 2001; Costa et al., 2004). This protein is widely expressed in the brain, 
with variable levels of expression depending of the region (Paulson et al., 1997; Trottier et al., 
1998). As regional localization of ataxin-3 expression does not match completely with 
neurodegenerated regions in MJD, it was suggested that cellular ataxin-3 expression is not by 
itself sufficient to cause neurodegeneration, and other cell-specific factors must be involved to 
explain the pathology (Paulson et al., 1997; Schmidt et al., 1998). 
The localization of ataxin-3 is predominantly cytoplasmatic (Paulson et al., 1997; Schmidt et 
al., 1998), although it is also detected in the nucleus where it accumulates upon polyglutamine 
expansion (Wang et al., 1997; Tait et al., 1998; Evert et al., 1999). 
1.2.4.2. Structure and domains 
Ataxin-3 belongs to the family of cysteine proteases. Structurally, it is composed of 339 
aminoacids and by a variable number of glutamines, which constitute the polymorphic 
polyglutamine tract (poly-Q tract) (Kawaguchi et al., 1994). Ataxin-3 is composed of a globular 
N-terminal Josephin domain with a papain-like fold, combined with a flexible C-terminal tail 
that contains 2 or 3 ubiquitin interaction motifs (UIMs), that binds polyubiquitylated proteins 
with a strong preference for chains containing four or more ubiquitins, and the poly-Q tract 
(Burnett et al., 2003; Masino et al., 2003) (Fig.1.3). It has been reported that the 3UIM ataxin-3 
protein is the predominant isoform in the central nervous system (Harris et al., 2010).  
The Josephin domain is an important functional region of ataxin-3 that plays a role both in 
the normal and in the pathological functions of the protein. There are evidences that 
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thermodynamic stability of ataxin-3 is driven by the properties of the Josephin domain, but the 
presence of an expanded polyQ tract increases drastically the protein’s tendency to aggregate 
(Masino et al., 2004; Tzvetkov and Breuer, 2007). 
The josephin domain has two additional Ub binding surfaces, one is close to the active site 
(site 1) and the second Ub-binding site (site 2) coincides with the interaction surface of the Ub-
like (Ubl) domain of hHR23B (Nicastro et al., 2005). The Ub-binding site 1 is indispensible for 
the enzymatic activity of ataxin-3, while site 2 may be dedicated to the recognition of hHR23 
proteins (Nicastro et al., 2010). 
 
 
 
Figure 1.3. Atxaxin-3 protein structure. Shown are the three predicted UIM regions of ataxin-3, the 
polyQ domain, the conserved Josephin domain encoding a predicted ubiquitin-specific protease with 
catalytic triad (Cys14, His119, and Asn136), a nuclear export signal (NES) and nuclear localization signal 
(NLS). 
 
The catalytic activity is mediated by a glutamine upstream of a cysteine in the JD N-terminal 
part and a histidine and an asparagine or aspartate in the JD C-terminal part. The cysteine, the 
histidine, and the asparagine constitute the catalytic triad characteristic of cysteine proteases 
(Albrecht et al., 2004). 
A highly conserved, putative nuclear localization signal (NLS), is found upstream of the 
polyQ stretch. This NLS follows a potential casein kinase II (CK-II) phosphorylation site, which 
may determine the rate of the observed ataxin-3 transport into the nucleus (Tait et al., 1998). 
Ataxin-3 may also contain two nuclear export signals (NES 77 and NES 141) following the 
Josephin domain. The localization of the NES signals in the N-terminal region, predicted to be 
cut-off from the NLS- and polyglutamine-containing C-terminal part of ataxin-3 in its aberrant 
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form, could explain important aspects of the pathogenesis of SCA3 (la Cour et al., 2003; 
Antony et al., 2009). 
 
1.2.4.3. Functions 
Ataxin-3 is a deubiquitylating enzime (DUB), being part of the Josephin family, and initial 
insights suggest that it has both nuclear and cytoplasmic functions (Li et al., 2002). The 
presence of UIMs in ataxin-3 raised the possibility that ataxin-3 is normally an ubiquitin-
binding protein and that its colocalization to ubiquitin-conjugated protein inclusions is mediated 
by this property. Therefore, it was reported that ataxin-3 binds and hydrolyses polyubiquitin 
chains (Doss-Pepe et al., 2003; Chai et al., 2004; Berke et al., 2005; Burnett and Pittman, 
2005), interacts with ubiquitinated proteins and can associate with the proteasome through 
interactions with the ubiquitin- and proteasome-binding factors Rad23 and valosin-containing 
protein (VCP/p97) (Doss-Pepe et al., 2003; Zhong and Pittman, 2006; Wang et al., 2007), p45 
(Wang et al., 2007) and Ubxn-5 (Rodrigues et al., 2009). Additionally, it was shown that the 
DUB activity and UIMs of Atx3 are required for aggresome formation (Burnett and Pittman, 
2005). Polyglutamine expansion may affect the interactions of Atx3 with other proteins and/or 
affect its DUB activity. Although there are evidences that wild-type and pathological Atx3 have 
very similar DUB activity, pathological Atx3 cleaves short ubiquitin chains more efficiently 
than does wild-type Atx3 (Burnett et al., 2003).  
Ataxin-3 has been also implicated in the cytoskeletal network. In vitro, the absence of Atx3 
leads to an overt cytoskeletal/adhesion defect. Cells display fewer projections and present 
evident cytoskeletal disorganization, loss of cell adhesion and increased cell death (Rodrigues et 
al., 2010).  
Ataxin-3 function was also associated to Endoplasmic reticulum (ER)- associated 
degradation (ERAD), which eliminates misfolded ER proteins by exporting them into the 
cytosol for degradation by the ubiquitin–proteasome system (Meusser et al., 2005). Atx3 is 
suggested as a shuttling factor with an involvement of its deubiquitinating activity in ER-
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associated protein degradation regulation (Kuhlbrodt et al., 2005). There are evidences that 
ataxin-3 interacts with the retrotranslocation complex consisting of Derlin-1, VIMP, certain ER-
specific ubiquitin ligases, and the ATPase p97 in the ER membrane. The expression of the poly-
Q–expanded atx3 mutants may also impair ERAD and trigger ER stress, which may contribute 
to the pathogenesis of spinocerebellar ataxia (Wang et al., 2006; Zhong and Pittman, 2006). 
Ataxin-3 is also important for myogenesis through regulation of integrin subunit levels. 
Ataxin-3 was found to be strongly expressed in the early myotome of mouse embryos, and it 
depletion in cells perturbs the phenotypical response to differentiation. Moreover, levels of 
integrin subunits, as well as many other proteins implicated in the integrin signalling pathway, 
are altered in ataxin-3-depleted cells. These findings raise the possibility that ataxin-3 
contributes to muscle differentiation by preventing the degradation of integrin subunits through 
the ubiquitin-proteassome system (UPS) (do Carmo Costa et al., 2010). 
Furthermore, ataxin-3 seems to play a role in agressome formation. The stability and 
aggregation properties of non-expanded Atx3 are determined by the properties of the Josephin 
domain, but the presence of an expanded polyQ tract increases the protein’s tendency to 
aggregate. Polyglutamine expansion may affect the interactions of Atx3 with other proteins and 
affect its DUB activity (Masino et al., 2004; Burnett and Pittman, 2005; Masino et al., 2011).  
Recently, was shown that the absence of ataxin-3 leads to an enhanced stress response in C. 
elegans. This phenotype was correlated with a distinct transcriptomic and proteomic profile 
with several molecular chaperones abnormally up-regulated during heat shock and recovery. 
These evidences are important in disease context. Long-term deregulation of heat-shock 
proteins (HSPs) can be detrimental for cell growth, division and viability (Feder et al., 1992; 
Krebs and Feder, 1997) and, along with the proteotoxic stress; this may contribute to neuronal 
demise in the context of MJD (Rodrigues et al., 2011).  
 INTRODUCTION 
14 
 
1.3. Protein clearance mechanisms  
A common cytopathological feature of the polyglutamine disorders, as well as other 
neurodegenerative disorders, is an intracellular deposition of aggregated and ubiquitinated 
poteins. The aggregated forms of these proteins and their intermediate forms, in most of cases, 
present toxic and pathological features, and may lead to the impairment of protein clearance 
mechanisms (Bence et al., 2001; Bennett et al., 2005; Rubinsztein, 2006). 
Eukaryotic cells have two main pathways for protein degradation: the ubiquitin- proteasome 
system and the autophagy- lysosomal pathway, which constitute essential components of the 
cellular quality systems (Ciechanover, 2005). 
 
1.3.1. Ubiquitin-Proteasome system  
The UPS is responsible for a highly selective degradation of short-lived and misfolded 
proteins present in cytoplasm and nucleus. The system involves the targeting of susceptible 
unfolded proteins by ubiquitin and to be degraded by this system (Fig. 1.4). 
The degradation of a protein via the ubiquitin-proteasome pathway involves two steps: 
tagging of the substrate by covalent attachment of multiple ubiquitin molecules and degradation 
of the tagged protein by the 26S proteasome complex with release of free and reusable 
ubiquitin. This process is mediated by ubiquitin recycling enzymes DUBs. Activation and 
conjugation of ubiquitin to the protein substrate proceeds via multi- step reactions, catalysed by 
E1 -ubiquitin-activating enzyme, E2 -ubiquitin-conjugating enzyme, and E3 -ubiquitin-protein 
ligase (reviewed by (Ciechanover, 2001; Glickman and Ciechanover, 2002; Ciechanover, 2005). 
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Figure 1.4. The ubiquitine-proteosome system. Adapted from Wong and Cuervo, 2010. 
 
1.3.2. Autophagy  
Autophagy, or cellular self-digestion, is a cellular pathway in which dysfunctional proteins 
and organelles are transported to lysosomes for degradation. These single membrane vesicles 
contain in their lumen the largest variety of cellular hydrolases including proteases, lipases, 
glycosilases and nucleases (De Duve and Wattiaux, 1966). Christian de Duve was awarded the 
Nobel Prize for the discovery of lysosome in 1974. However, only in the last years the 
autophagy pathway has been intensively explored and its mechanisms elucidated (Harding et 
al., 1996; Klionsky et al., 2003; Wang and Klionsky, 2003). 
Depending on the type of cargo and the cellular conditions, cargo recognition and delivery 
occurs by different mechanisms, giving rise to different modalities of autophagy (Mizushima et 
al., 1998; Yang et al., 2002; Yang and Klionsky, 2009). The three major intracellular pathways 
in eukaryotic cells are macroautophagy, microautophagy and chaperone-mediated autophagy 
(CMA) (Fig.1.5). In macroautophagy, a whole region of the cytosol is sequestered into a 
double-membrane vesicle that fuses with lysosomes for cargo delivery. By contrast, 
microautophagy involves the direct engulfment of cytoplasm that is internalized into the 
lysosomal lumen as a single membrane vesicle, whereas in CMA a targeting motif is recognized 
by chaperones that mediate the translocation of unfolded, soluble proteins directly across the 
limiting membrane of the lysosome (Yang and Klionsky, 2009; Wong and Cuervo, 2010). 
Several cellular functions have been associated with autophagy. This clearance pathway is 
responsible to remove the damage long-lived protein and the organelles and contribute for 
normal turnover of these intracellular components, playing a key role in cellular quality control. 
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Furthermore, autophagy has also the main function of maintenance of the cellular energetic 
balance, providing a cellular adaptive response to stress conditions (Singh and Cuervo, 2011). 
 
 
Figure 1.5. Autophagy pathways. (A) Macroautophagy (B) Microautophagy (C) Chaperone- 
mediated autophagy (CMA) Adapted from Wong and Cuervo, 2010. 
 
There are more than 30 autophagy-identified genes in yeast and many of these have 
mammalians orthologs. These authophagy-related genes (ATG) can be grouped according to the 
functions of their products (ATG proteins), which are involved in regulation of different steps of 
the autophagy pathway: initiation, elongation, maturation, and fusion with the lysosome 
(Mizushima et al., 1998; Mizushima et al., 2002)  
  
1.3.2.1. Autophagy pathway 
 
Initiation 
Autophagy occurs at basal levels under normal conditions, however this phenomenon can be 
up-regulated by specific stress factors such as starvation, hypoxia, oxidative stress, toxin 
exposure, among others (Kiffin et al., 2004; Zhang et al., 2008)  
The induction of autophagy is mediated through the mammalian target of rapamycin (mTor)-
dependent and independent pathways. The serine/threonine protein kinase mTOR is the central 
inhibitor of autophagy, which is activated upon nutrient rich conditions and inhibited by 
rapamycin administration or under starvation conditions, up-regulating autophagy. The mTOR 
kinase integrates input information from several upstream transduction pathways, such as 
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insulin, class I Phosphatidylinositol-3-kinase (PI3K) and Akt (Laplante and Sabatini, 2009; 
Sengupta et al., 2010) and also negatively regulates autophagy related protein 1 (Atg1), and 
other serine/threonine kinase proteins like (Unc- 51- Like Kinase1 and 2) (ULK-1 and 2) which 
are the mammalians homologs (Chan and Tooze, 2009; Ganley et al., 2009). The ULK-1 and 2 
are in a large complex that includes the mammalian homolog of Atg17, focal adhesion kinase 
family-interacting protein of 200 Kda (FIP 200), and the mammalian Atg13. The complex 
formed has a key role in the induction of autophagy. A decrease in mTOR activity leads to 
dephosphorylation of ULK1, ULK2 and Atg13, activating ULK1/2, which phosphorylates 
FIP200 and to induce autophagosome formation (Chang and Neufeld, 2009; Ganley et al., 2009; 
Hara and Mizushima, 2009; Hosokawa et al., 2009; Jung et al., 2009).  
The formation of the phagophores, the precursors of autophagosomes, is the inicial step of 
macroautophagy pathway (Fig.1.6). The membrane source from which phagophores arise is still 
an issue of debate. There are studies that support different hypothesis: a) autophagosomes can 
be generated de novo from preexisting intracellular precursors (Hirsimaki et al., 1982; Baba et 
al., 1995); several organelles can contribute for autophagosomes formation such as b) ER 
(Dunn, 1990; Kim and Klionsky, 2000; Axe et al., 2008; Hayashi-Nishino et al., 2009; Yla-
Anttila et al., 2009; Matsunaga et al., 2010); c) Golgi complex, mainly in Yeast (Reggiori et al., 
2004; Geng et al., 2010; van der Vaart et al., 2010); d) mitochondria, which may be a 
membrane source during starvation (Hailey et al., 2010; Tooze and Yoshimori, 2010) or e) 
plasma membrane (Ravikumar et al., 2010). 
The autophagosome formation start with the interaction of ULK complex with another 
kinase complex, the autophagy-regulating macromolecular complex (PI3K complex) to induce 
the formation of the phagophore, nevertheless autophagy can be induced in an mTOR-
independent way by direct activation of the class III PI3K complex or Beclin-1. 
The class III PI3K is a crucial protein regulating the nucleation of the phagophore. Vps34, 
which is part of the PI3K complex is responsible for the formation of phosphatidylinositol-3-
phosphate (PI-3-P), which has been implicated in the recruitment of Atg proteins, essential for 
the formation of the phagohore (Petiot et al., 2000; Axe et al., 2008). Other autophagy-related 
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proteins are found in the same complex including Beclin-1/ Atg6, Atg14/barkor, and 
p150/Vps15, UVRAG (UltraViolet irradiation Resistant-Associated Gene) and Ambra 1 
(Volinia et al., 1995; Kihara et al., 2001; Fimia et al., 2007; Itakura et al., 2008; Liang et al., 
2008; Sun et al., 2008). Beclin-1 has been correlated with autophagy activity since 
heterozygous deletion of beclin-1 leads to neurodegeneration (Pickford et al., 2008) and the 
overexpression of this protein reflects an increase of autophagy in response to pathogenic 
proteins (Erlich et al., 2006; Nascimento-Ferreira et al., 2011). Beclin-1 binding partners like 
ambra-1, UVRAG, and bif-1 have been identified as essential to autophagosome formation. On 
the other hand, anti-apoptotic proteins Bcl-2 or Bcl-X negatively regulate this pathway 
(Pattingre et al., 2005). 
 
Elongation 
The step following the nucleation of the phagofore is the expansion and elongation of the 
membrane. Therefore, two ubquitin-like reactions are required. First, the ubiquitin-like protein 
Atg12 is conjugated to Atg5, reaction mediated by Atg7 (E1 ubiquitin activating enzyme-like) 
and Atg10 (E2 ubiquitin conjugating enzyme-like) (Mizushima et al., 1998). Then, Atg12-Atg5 
is conjugated with Atg16L, resulting in a large multimeric complex with 800-kDa called 
Atg16L complex, localized in the isolation membrane.  
In the other ubiquitin-like reaction, occurring in parallel, the mammalian homologue of 
Atg8, LC3 is synthesized as precursor form (pro-LC3) and cleaved by the cystein protease Atg4 
to generate LC3-I, a cytosolic form of the protein (Hemelaar et al., 2003). Next, LC3-I is 
activated by E1 Atg7 (Tanida et al., 2001) and transferred to the active-site cystein of the E2 
Atg3, which then conjugates to phosphatidylethenolamine (PE) to form LC3-II (Noda et al., 
2008; Oh-oka et al., 2008). LC3-II and the Agt16L complex are essential for growth and 
expansion of phagophore. Atg16L determines where the autophagosome membrane expansion 
starts, indicating the sites of LC3 lipidation (Mizushima et al., 2002; Fujita et al., 2008) and 
LC3-II, in turn, will lead to elongation of the isolation membrane (Nakatogawa et al., 2007; 
Weidberg et al., 2011). 
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Since LC3-II associates specifically with autophagosomes membranes and remains bound 
even after fusion with lysosomes, LC3-II levels can be correlated with the number of 
autophagosomes present in the cell, which is the basis of many assays to measure autophagic 
flux (Kabeya et al., 2000; Klionsky et al., 2008; Rubinsztein et al., 2009). 
 
Cargo sequestration 
Although autophagy was previously considered a nonselective bulk degradation pathway, in 
the last few years, several evidences support the selectivity of the sequestration of autophagic 
cargo (Kraft et al., 2009). Selective autophagy may be possibly involved in the recognition of 
post-translational modification such as ubiquitination or acetylation (Jeong et al., 2009; Kirkin 
et al., 2009). 
The first cargo-recognizing molecule described was the sequestosome 1/p62 (SQSTM1/p62), 
which was reported to bind ubiquinated protein aggregates and through it interaction with LC3 
brings autophagosome formation to these aggregates (Bjorkoy et al., 2005; Tan et al., 2008). 
Later on, other molecules were reported to be able to recognize signals from ubiquitin, which is 
the case of neighbor of BRCA1 gene 1(NBR1) (Pankiv et al., 2007; Kirkin et al., 2009; Lamark 
et al., 2009). 
Changes in substrates as well as in the autophagic system could lead to inefficient cargo 
recognition and consequently to autophagic failure (Martinez-Vicente et al., 2010). 
 
Maturation and Fusion 
In the final steps of the autophagic pathway, the autophagosome vesicules may fuse with 
lysosomes, forming autolysosomes (Fig.1.6). For that, autophagosome are transported along 
microtubules towards lysosomes, in the perinuclear region, using the dynein-dynactin complex 
(Ravikumar et al., 2005; Jahreiss et al., 2008; Kimura et al., 2008).  
The machinery involved in the fusion of autophagosomes to the lysosome include proteins 
such as ESCRT, SNAREs, Rab7, and the class C Vps proteins (Atlashkin et al., 2003; Gutierrez 
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et al., 2004; Rusten et al., 2007; Furuta et al., 2010). Also the UVRAG protein, a Beclin 1 
interacting protein, is involved in this process through the recruitment of class C Vps complex. 
This interaction stimulates Rab7 GTPase activity and autophagosome fusion with late 
endosomes/ lysosomes, consequently increasing delivery and degradation of the autophagic 
cargo (Gutierrez et al., 2004; Liang et al., 2008). 
Furthermore, also lysosome activity is crucial to the efficient cargo degradation. Studies 
using bafilomycin A1 or chloroquine, which inhibit the intra-lysosomal acidification, have 
described a blockage of the fusion of autophagosomes with lysosomes (Yamamoto et al., 1998; 
Jahreiss et al., 2008). Due to their ability to inhibit the acidification and the consequent 
accumulation of autophagosomes, these molecules are often used to measure the autophagic 
flux in the cells (Perry et al., 2009; Zois et al., 2011). 
 
 
 
 
 
 
1.3.2.2. Autophagy and neurodegeneration 
 
Several evidences reveal that one of the areas where autophagy appears to be crucial is to 
prevent neurodegeneration and therefore, alterations in the different steps of this clearance 
Figure 1.6. Autophagy pathway and machinery. Several regulatory signals activate the recruitment 
of the autophagy initiation complex. Current evidence suggests that multiple compartments, including 
the endoplasmic reticulum, Golgi, mitochondria, and the plasma membrane may act as lipid donors to 
the growing phagophore. Beclin-vps34complex regulates the formation of phagophore. Two ubiquitin-
like conjugation systems are involved in the elongation step. The Atg5-Atg12 congugation involves 
Atg7 (E1-like) and Atg10 (E2-like), while Atg7 and Atg3 act as the E1-like and E2-like, respectively, 
in LC3-PE conjugation. Once the membrane seals to form the autophagosome, this double membrane 
vesicle is delivered to lysosomes where, upon membrane fusion, lysosomal hydrolases gain access to 
cargo. Adapted from Sridhar et al., 2012 
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process might be intimately linked to many human diseases (Fig. 1.7). The first indication of 
altered autophagy in different neurodegenerative conditions is the presence of an abnormal 
number of autophagosomes in the affected neurons (Roizin et al., 1974; Anglade et al., 1997; 
Nixon et al., 2005). Another proof of the importance of autophagy was demonstrated in studies 
using knockout mice for Atg5 or Atg7, where it was observed that the impaired autophagy 
function led to the accumulation of ubiquitin-positive inclusions and to the development of 
characteristic symptoms of neurodegeneration in these mice (Hara et al., 2006; Komatsu et al., 
2006). 
Although basal autophagy has an important function in healthy individuals, the requirement 
for autophagy is even more evident under disease conditions, supporting the idea that autophagy 
induction might be a suitable therapeutic strategy in a range of adult-onset neurodegenerative 
diseases.  
Intracellular protein aggregates and dysfunctional organelles are common features of 
neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and 
polyglutamine diseases like HD and spinocerebellar ataxias (SCAs). In these disorders, the 
pathology is associated with the protein propensity to aggregate and accumulate in specific 
types of neurons, leading to neuronal dysfunction (Rubinsztein, 2006; Imarisio et al., 2008). 
Therefore, in the presence of toxic proteins, autophagy upregulation has also been shown to be 
beneficial. In Alzheimer’s disease, for example, the amyloid beta (Aβ) peptide and the amyloid 
precursor protein (APP)-derived fragment (APP-CTF) are cleared upon autophagy induction 
(Tian et al., 2011). In Parkinson’s disease, when a lentivirus expressing beclin-1 was delivered 
to the brain of a α-synuclein transgenic mouse, the synaptic and dendritic pathology was 
ameliorated and the accumulation of α-synuclein in the limbic system was reduced (Spencer et 
al., 2009). The same strategy was performed in MJD models, resulting in the clearance of 
mutant ataxin-3 and the mitigation of neuropathology (Nascimento-Ferreira et al., 2011). In 
addition, in HD it was demonstrated that rapamycin attenuates huntingtin accumulation and cell 
death in cell models of HD (Ravikumar et al., 2004) and later, others studies probed the 
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therapeutic potential of autophagy induction in various models of HD (Ravikumar et al., 2003; 
Sarkar et al., 2007). 
One important factor in polyglutamine diseases when considering up-regulation of 
autophagy is the cellular distribution of polyQ inclusions, since in diseases like SCA3/MJD, 
SC7, SCA17, SBMA, HD, Dentatorubral-Pollidoluysian Atrophy (DRPLA) these aggregates 
can be found in the nucleus. This is relevant because autophagy is described as a cytoplasmic 
mechanism, in view of the fact that there are not lysosomes in the cell nucleus (Klionsky and 
Emr, 2000; Cuervo, 2004; Montie et al., 2009). Autophagy has been shown to eliminate 
cytoplasmic polyglutamine-containing aggregates more efficiently than nuclear aggregates 
(Iwata et al., 2005) and this differential efficiency of degradation could explain the greater 
toxicity associated with intranuclear inclusions in the diseases where both cytoplasmic and 
nuclear aggregates are present (Yang et al., 2002). 
If and how nuclear aggregates are degraded by autophagy is currently debated. Degradation 
of aggregate precursors may occur at the cytoplasm before their translocation to the nucleus 
(Rubinsztein, 2006; Li et al., 2008); or there may be shuttling of nuclear aggregates to the 
cytoplasm, regulated by acetylation and phosphorylation (Jeong et al., 2009; Thompson et al., 
2009). 
 
 
 
 
 
 
 
Figure 1.7. Possible steps of autophagy altered in neurodegeneration. (1) reduced autophagy 
induction; (2) enhanced autophagy repression; (3) altered cargo recognition; (4) inefficient 
autophagosome/lysosome fusion, and (5) inefficient degradation of the autophagic cargo in lysosomes. 
Examples of neurodegenerative diseases for which alterations in each autophagic step have been 
described are shown. Atg, autophagy-related proteins; Vps, vesicular protein secretion protein; GβL, G 
protein beta protein subunit-like; HDAC, histone deacetylase; AD, Alzheimer’s disease; HD, 
Huntington’s disease; PD, Parkinson’s disease; LSD, lysosomal storage disorders; SMA, spinal muscular 
atrophy. (Wong and Cuervo, 2010). 
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1.3.2.3. Strategies for modulation of autophagy  
 
There are several pathways and small molecules that regulate autophagy, via mTor and 
mTor-independent mechanisms. The knowledge of these mechanisms allows their modulation 
in order to inhibit or to activate this clearance pathway.  
In the sections below we will focus in strategies to activate autophagy, with special interest 
on therapeutic approaches for polyglutamine diseases. 
 
Activation of autophagy through mTor-dependent pathways 
The mTOr is the most studied pathway regulating mammalian autophagy (Codogno and 
Meijer, 2005). Many factors such as growth factors, nutrient signals and energy status affect the 
mTor pathway (Fig.1.8) (Loewith et al., 2002; Sarbassov et al., 2005). The mTor exists in two 
functional complexes: mTor complex 1 (mTorC1), sensitive to rapamycin, and mTor complex 2 
(mTorC2); both containing mTor catalytic subunit and G protein β-subunit-like protein, or 
mLST8 (GβL) but differing in their other subunits (Sarbassov et al., 2005). The activity of 
mTorC1 can be inhibited by rapamycin and its analogs, activating autophagy both in vitro and 
in vivo (Ravikumar et al., 2002; Ravikumar et al., 2004). First isolated from Streptomyces 
hygroscopicus (Montgomery et al., 1998) rapamycin until recently was the only drug known to 
upregulate autophagy (Guertin and Sabatini, 2009). Later, other inhibitors of mTor have been 
described. In a study screening a library of 3500 chemicals, perhexiline, niclosamide, 
amiodarone, and rottlerin were identified as stimulators of autophagy by inhibiting mTorC1 
signiling; three of those are drugs already approved for other therapeutic approaches (Balgi et 
al., 2009). Also, Adenosine triphosphate (ATP)-competitive inhibitors of mTOR such as Torin1 
(Thoreen et al., 2009) and PP242 (Feldman et al., 2009) show high inhibitory activity of 
mTOR. 
Nevertheless, as mTor is a central regulator of many cellular processes, the long term 
treatment of diseases like MJD with mTor inhibitors could lead to several complications, since 
these molecules are not specific inducers of autophagy. 
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Figure 1.8 mTor-dependent pathways. The PI3K pathway is triggered by the binding of insulin (or 
growth factors) to insulin receptor (IR), thereby activating PI3K. Activated PI3K converts PIP2 to PIP3, 
which then recruits phosphoinositide-dependent kinase 1 (PDK1) and Akt to the cell membrane. Akt is 
then phosphorylated and activated which, in turn, inhibits the tuberous sclerosis complex  (TSC)1/2, and 
activates the smallGTPase Rheb, resulting in mTORC1 activation. The ULK1-Atg13-FIP200 complex 
acts as an integrator of the autophagy signals downstream of mTORC1. Under starvation conditions or 
rapamycin treatment, mTOR dissociates from this complex, resulting in dephosphorylation-dependent 
activation of ULK1 and ULK1-mediated phosphorylations of Atg13, FIP200, and ULK1 itself, which 
triggers autophagy. Torin1, perhexiline, niclosamide and rottlerin also inhibit mTORC1 activity, either 
directly or indirectly. The vitamin E antioxidant activates the mTOR pathway and inhibits autophagy. 
Adapted from Ravikumar et al., 2010. 
 
Activation of autophagy through mTor-independent pathways 
In order to overcome the limitation of mTor-dependent autophagy inducers, it is important to 
explore novel targets aiming different autophagy inducing pathways. Accordingly, a study using 
image-based assays identified eight compounds that induce autophagy and promote long-lived 
protein degradation in expanded polyglutamine cell model (Zhang et al., 2007). The compounds 
analysed can be divide in two classes: the class 1 consist of three Food and Drug Administration 
(FDA)-approved antipsychotic drugs, fluspirilene, trifluoperazine, and pimozide and the class 2 
compounds consist of five compounds, including three FDA-approved drugs for cardiovascular 
indications, niguldipine, nicardipine and amiodarone, that inhibit intracellular Ca
2+
 currents, 
loperamide, a FDA approved drug for diarrhea, and penitrem A. The phosphorylation status of 
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mTOR in cells treated with these eight compounds was not altered compared with rapamycin, 
which permit to conclude that these compounds induce autophagy through mechanisms distinct 
from that of rapamycin. Furthermore, seven of these molecules present lower cytotoxicity than 
rapamycin, suggesting that it should be possible to use these drugs in the treatment of human 
diseases characterized by accumulation of misfolded proteins (Zhang et al., 2007). 
Later on, another study screening 253 FDA approved drugs was performed to identify novel 
autophagy-inducing pathways and to evaluate their effects in the clearance of huntingtin. The 
drugs analysed exhibit a cyclical mTOR-independent pathway regulating autophagy, where 
cyclic adenosine monophosphate (cAMP) regulates inositol (IP3) levels, influencing calpain 
activity, which completes the cycle by cleaving and activating Gsα, which regulates cAMP 
levels (Fig. 1.9) (Williams et al., 2008). 
 
Figure 1.9. mTor-independent pathways. The cyclical mTOR-independent pathway consists of the 
cAMP-Epac-PLC-e, phosphoinositol and Ca
2+
-calpain-GSα pathways. Intracellular cAMP levels are 
increased by adenylyl cyclase (AC), which activates Epac. Epac in turn activates a small G protein 
Rap2B, which activates phospholipase C (PLC), resulting in the production of IP3 and consequently 
releasing Ca
2+
 from the endoplasmic reticulum (ER) stores. Intracytosolic Ca
2+
 levels are also increased 
by Ca
2+
 influx due to L-type Ca2+ channel agonist binding. Increase in intracytosolic Ca2+ activates the 
cysteine protease called calpains, which cleave and activate GSα. GSα activation results in an increase in 
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AC activity elevating cAMP levels, therefore as part of a loop. Activation of this pathway inhibits 
autophagy. Drugs targets acting at distinct stages within the cAMP-Epac-PLC-e, phosphoinositol, and 
Ca
2+
-calpains-Gsα pathways induce autophagy, such as imidazoline-1 receptors (I1R) agonists and 
adenylyl cyclase inhibitors which decrease intracellular cAMP levels, inositol-lowering agents (lithium, 
L-690,330, sodium valproate and carbamazepine), L-type Ca
2+
 channel antagonists, calpain inhibitors 
(calpastatin and calpeptin) , and Gsα inhibitors. Adapted from Ravikumar et al., 2010. 
 
Regulating the cAMP-Epac-PLC-e pathway 
cAMP negatively regulates autophagy through Epac-PLCe signalling, culminating on the 
modulation of IP3 levels. It was observed that pharmacological treatment with imidazoline-1 
(I1R) receptor agonists, such as clonidine and rilmenidine, or the adenylyl cyclase inhibitor 
20,50- dideoxyadenosine, induce autophagy by reducing cAMP levels (Williams et al., 2008). 
These drugs revealed the ability to induce autophagy in several models of HD, like cell culture 
models, zebrafish, flies and mouse models (Williams et al., 2008; Rose et al., 2010). 
Furthermore, these studies indicate the possibility of using cAMP modulators to treat 
polyglutamine diseases, since some of them are already used in other therapeutic indications. 
 
Regulating the Ca
2+
-calpain-GSa pathway 
In the same study carried out by William and collaborators (2008), it was shown that L-type 
Ca
2+
 channel antagonists, such as verapamil, loperamide, amiodarone and nitrendipine induce 
autophagy. These drugs prevent the influx of extracellular Ca
2+
 through the inhibiting of L-type 
Ca
2+ 
channels on the plasma membrane and thereby decreasing intracytosolic Ca
2+
 levels, which 
result on up-regulated autophagy. Some of these Ca
2+ 
channel blockers were also reported in the 
study of Zhang and collaborators (Zhang et al., 2007). On the other hand, elevated 
intracytosolic Ca
2+
 levels activate a family of cystein proteases, calpains, leading to inhibition of 
autophagy. Nevertheless this effect can be reverted with chemical inhibition of calpain by 
calpastatin and calpeptin; which has also been confirmed in this screen (Williams et al., 2008).  
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Regulating PhosphoInositol or IP3 pathway 
The phosphoinositol pathway was the first alternative mechanism described as increasing 
autophagy independently of mTor, by reducing intracellular levels of IP3 (Sarkar et al., 2005). 
This pathway is stimulated by G protein coupled receptor-mediated activation of phospholipase 
C (PLC), which hydrolyses PIP2 to form IP3 and diacylglycerol (DAG) (Berridge, 1987). IP3 is 
a second messenger and acts on the IP3 receptor (IP3R), a mostly ER Ca
2+
 release channel that 
integrates a variety of cell signals (Berridge et al., 2003). 5’-phosphatase and inositol 
polyphosphate 1-phosphatase (IPPase), and Inositol monophosphatase (IMPase) are required 
first to form inositol monophosphate (IP1) and second to catalyze the hydrolysis of IP1 into free 
inositol, essential for the phosphoinositol signaling (Maeda and Eisenberg, 1980; Majerus, 
1992). 
Mood-stabilizing drugs such as lithium (Li), valproic acid (VA) and Carbamazepine (CBZ) 
act in this pathway by reducing inositol levels and increasing autophagy (Williams et al., 2002). 
Therefore, treatment with these drugs has been shown to promote an enhanced clearance of 
misfolded proteins such as mutant huntigtin in various HD models, and the A53T and in A30P 
mutants of α-synuclein (Sarkar et al., 2005; Sarkar et al., 2008; Williams et al., 2008). The 
autophagy-inducing ability of lithium is attributed to its IMPase-inhibitory effect in the 
phosphoinositol signaling pathway, lowering inositol and IP3 levels. A specific IMPase 
inhibitor (L-690,330) and mood-stabilizing drugs such as CBZ and valproic acid have similar 
effects on activation of autophagy and on the clearance of aggregate-prone proteins. 
Furthermore, consistent with a role of IP3 on autophagy, a study has shown that autophagy can 
also be enhanced by genetic knockdown of IP3Rs (Criollo et al., 2007). 
In this work we are focus in the activation of autophagy through the phosphoinositol 
pathway, in particular using CBZ as an autophagy-enhancing drug. 
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Carbamazepine 
CBZ belongs to the therapeutic class of antiepileptic, neurotropic and psycotropic agents. 
Discovered in 1953 by Walter Schindler, CBZ was introduced in the market in 1962 first 
indicated as anticonvulsant and for treatment of trigeminal neuralgia, and later as antiepileptic.  
The mechanism of action of CBZ is still unclear. Nevertheless, it is known that CBZ acts 
on the stabilization of hiperexcited neuronal membranes and limits repetitive firing of action 
potentials, by blockage of voltage-dependent neuronal sodium channels. It also affects calcium 
channels, g -amino butyric acid (GABA) receptors, and adenosine receptors, and increases 
concentrations of serotonin and other neurotransmitters. While the reduction of glutamate 
release and the stabilization of neuronal membranes can contribute primarily to the antiepileptic 
effects, the depressing effect on the "turnover" of dopamine and norepinephrine can be 
responsible for the anti-manic properties of CBZ (Ambrosio et al., 2002). 
CBZ is almost completely absorbed, and the plasma levels of CBZ in the steady state are 
reached after about 1 to 2 weeks. The half-life of CBZ is approximately 36 hours after a single 
oral dose, whereas after repeated administration is, on average, only 16-24 hours, depending on 
the duration of the treatment. This drug is metabolized in the liver, by cytochrome P450 3A4 
(Bertilsson, 1978). 
In addition to the therapeutic indications currently used in the clinic, recent evidences 
reveal a role of this drug in activation of autophagy (Hidvegi et al., 2010). As described above, 
mood stabilizing drugs have shown capacity to up-regulate autophagy by lowering IP3 levels, 
which might be a viable alternative to mTor inhibitors (as rapamycin) in the treatment of 
diseases characterized by accumulation of aggregate-prone proteins. Thus, besides the evidences 
of lithium potential in the clearance of huntingtin (Sarkar et al., 2005; Williams et al., 2008), 
CBZ appears as an autophagy enhancing drug, promoting degradation of Mutant α1-antitrypsin 
Z and reducing hepatic Fibrosis (Hidvegi et al., 2010). Based on these findings this drug might 
be promising also in neurodegenerative disorders such as Machado –Joseph disease.  
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OBJECTIVES 
 
The general objective of this work was to study the carbamazepine (CBZ) effect in Machado 
Joseph disease, concerning the described ability to enhance autophagy and promote clearance of 
the aggregate prone proteins. 
The specific objectives were as follows: 
 To investigate the activation of autophagy mediated by CBZ in a cellular model. 
 To evaluate the best conditions of CBZ treatment in neuroblastoma cells, regarding 
the removal of all forms of mutant ataxin-3. 
 To analyze the effects of CBZ treatment at neuropathological level in a lentiviral-
based mouse model. 
 To investigate the effect of a short-term CBZ treatment in a transgenic mouse model, 
regarding autophagy activation and clearance of mutant ataxin-3. 
 To evaluate motor coordination and activity profile by motor behavior tests upon 
moderate/long-term administration of CBZ in a transgenic mouse model. 
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2.1. Lentiviral vectors 
The complementary DNAs encoding for rat light chain 3 (LC3) (Kabeya et al., 2000) fused 
to the enhanced green fluorescent protein (EGFP) were inserted downstream from the mouse 
phosphoglycerate kinase 1 promoter in a self-inactivating lentiviral transfer vector (de Almeida 
et al., 2001). Viral vectors encoding a) enhanced green fluorescent protein-light chain 3 (EGFP-
LC3) and b) human full length mutant ataxin-3 with 72 glutamines (Alves et al., 2008), were 
produced in human embryonic kidney 293 T cells using a four-plasmid system as previously 
described (de Almeida et al., 2002). The lentiviral particles were produced and resuspended in 
phosphate-buffered saline with 0.5% bovine serum albumin (PBS-BSA) and samples were 
matched for particle concentration by measuring human immunodeficiency virus 1 (HIV-1) p24 
antigen content (RETROtek, Gentaur, France). Viral stocks were stored at -80°C until use. 
2.2. In vivo experiments 
The animals were housed in a temperature-controlled room and maintained on a 12 h 
light/dark cycle. Food and water were available ad libitum. The experiments were carried out in 
accordance with the European Community Council directive (86/609/EEC) for the care and use 
of laboratory animals. 
2.2.1. Lentiviral MJD mouse model 
Experiments with the lentiviral MJD model involved injection of lentiviral vectors encoding 
the full-length mutant ataxin-3 with 72 glutamine repeats in the right hemisphere of the brain, in 
the striatum. Three weeks after treatment with CBZ or equivalent volume of dimethyl sulfoxide 
(DMSO), the animals were killed by sodium pentobarbital overdose, transcardially perfused 
with 0.1M PBS and a 4% paraformaldehyde fixative solution (PFA 4%, Fluka, Sigma, St. 
Louis, USA) followed by brain removal. The tissue was cryoprotected in 25% sucrose- 0.1M 
PBS solution for 48h , dry ice- frozen and cut at a cryostat-microtome (Leica CM3050S, Leica 
Microsystems Nussloch Gmbh, Nussloch, Germany) in 20µm coronal sections. Slices of each 
animal were collected and stored in 48-well trays (Corning Inc., NY, USA), free-floating in 
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0.1M PBS supplemented with 0.12 µmol/L sodium azide. The sections were stored at 4°C until 
immunohistochemical processing.   
 
2.2.1.1. Stereotaxic Surgery 
Mice with 3 weeks of age were anesthetized by intraperitoneal injection of a mixture of 
ketamine (100 mg/kg) with xylazine (10 mg/kg). Particle content of lentiviral vectors was 
matched to 200 000 ng of p24/ml (concentrated viral stocks were thawed on ice and 
resuspended by vortexing). The animals received a single injection of 2µl of lentiviral vectors at 
a rate of 0.25 µl/min by means of an automatic injector (Stoelting Co., Wood Dale, IL, USA), at 
the following coordinates: +0.6 mm rostral to lambda, -1.8 mm midline, and -3.3 mm ventral to 
the skull surface, with the mouth bar set at  -3.3. After the injection, the syringe needle was left 
in place for an additional 5 min to minimize backflow. 
 
2.2.1.2. Carbamazepine treatment 
CBZ was administered at 200 mg
-1
 kg
-1
 day
-1
 for 3 weeks by gavage and the equivalent 
volume of DMSO was given to the control group. 
 
2.2.2. Transgenic mouse model 
The Machado Joseph’s disease transgenic mouse model expressing the N-terminal-truncated 
ataxin-3 with 69 glutamine repeats and an N-terminal hemaglutinin (HA) epitope driven by 
Purkinje-cell-specific L7 promoter (Tg-MUT) has been previously described (Torashima et al., 
2008; Oue et al., 2009). A colony of these transgenic mice was established in the Center for 
Neurosciences and Cell Biology of the University of Coimbra and the line was maintained by 
backcrossing heterozygous transgenic males with C57BL/6 females. Genotyping was performed 
by PCR.  
Transgenic mice with 17 weeks old, were killed by sodium pentobarbital overdose, 
transcardially perfused with 0.1M PBS and a 4% paraformaldehyde fixate solution (PFA 4%, 
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Fluka, Sigma, St. Louis, USA) followed by brain removal. The brain was cryoprotected in 25% 
sucrose- 0.1M PBS solution for 48h, and stored at -80ºC. 
 
2.2.2.1. Carbamazepine treatment 
In one experiment CBZ (SIGMA) was administered at 250 mg
-1
 kg
-1
 day
-1
 for one week by 
gavage, in a group of animals. The equivalent volume of DMSO (SIGMA) was administered to 
control group, also by gavage. In another experiment, the same dose of CBZ was administered 
for 12 weeks orally in water solution, after solubilization in DMSO. Every two weeks the 
animals were subjected to a behavioural assessment. The equivalent volume of DMSO was 
given to control groups. Animals at 3 weeks of age were used in both experiments. 
 
2.2.2.2. Behaviour tests 
Rotarod. Rotarod tests were carried out to measure the motor coordinative abilities and 
balance of mice. Mice were tested using fix and accelerating rotarod, respectively (Letica 
Scientific Instruments, Panlab, Barcelona, Spain) starting at 4 rpm and accelerating to 40 rpm 
during a period of 300 sec (5 min). The latency to fall off the rotating rod was recorded in four 
trials per time-point, with 15 min rest between trials. The tests were repeated every two weeks. 
Statistical analysis of obtained data was performed calculating the mean values of three trials for 
each group (the trial with the most distant value from average was eliminated from the analysis). 
To evaluate statistical significance two-way ANOVA tests were performed in GraphPad 
software (La Jolla, USA). Data are represented as mean ± SEM. 
Open field analysis.  For the assessment of mice explorative behavior, and locomotor 
horizontal activity, open field tests were performed. Mice were placed in a 50x50 cm arena with 
50 cm high walls and their movement activity was recorded for 40 min using Acti-Track System 
(Panlab, Barcelona, Spain). The collected data was analyzed for the first 10 min in the arena, 
and for the last 30 minutes. Mean values for each measure was calculated. The statistical 
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analysis was performed by Two-way ANOVA, using the GraphPad software (La Jolla, USA). 
Data are represented as mean±SEM. 
 
2.3. Cell cultures 
2.3.1. Neuroblastoma cell culture 
Mouse neuroblastoma cell line (Neuro-2a cells) obtained from the ATCC cell biology bank 
(CCL-131) were incubated in DMEM medium (SIGMA) supplemented with 10% FBS, 
100U/ml penicillin and 100µg/ml streptomycin (Gibco, Paisley, Scotland, UK) (complete 
medium) at 37°C in 5% CO2/air atmosphere.   
 
2.3.1.1. N2A infection  
Cells were plated in 12 well plates; 2 x 10
5
 cells per well in 1000µl of medium and 24h later 
were simultaneously infected with lentiviral vectors expressing EGFP-LC3 and Atx3 MUT, or  
with only Atx3 MUT, at the ratio of 10 ng of p24 antigen/10
5
 cells. For the infection, we 
replaced the medium with 400µl of new medium and 1.6µl of hexadimethrin bromid (Aldrich) 
(8µg/ml) and added the corresponding lentivirus. The plates were then incubated at 37°C in 5% 
CO2/air atmosphere. After 6h of infection, we added 600µl of new fresh medium to the wells. 
At two weeks post-infection cells were treated with CBZ and lysed for western bloting analysis 
or fixed for immunocitochemistry analysis.   
 
2.4. mRNA expression analysis 
2.4.1. RNA extraction, Quality and Concentration analysis 
RNA of cerebellum lysates of transgenic mice and cell lysates were isolated using RNeasy 
Mini Kit, Qiagen and resuspended in 30µl of Rnase-free water. RNA concentration and purity 
was determined using the NanoDrop 2 000 spectrophotometer (Thermo). The RNA samples 
were stored at -80ºC until further use. 
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2.4.2. Reverse Transcription 
For complementary DNA (cDNA) synthesis 500 ng of isolated RNA was used mixed with 4 
μL  of 5x iScript Select Reaction Mix, 1 μL of Reverse Transcriptase, 2 μL random primer and 
Nuclease-free water for a total volume of 20 μL per experimental condition (iScript™ Select 
cDNA Synthesis Kit, Bio-Rad). The reaction was performed at 25 ºC for 5 min for primer 
annealing to the template, followed by 30 min at 42 ºC for cDNA synthesis. The reverse 
transcriptase was then denatured and inactivated for 5 min at 85 ºC. The sample was cooled to 4 
ºC, before storage at -20 ºC until further use. 
 
2.4.3. Quantitive Real-Time PCR 
PCR was carried out in a 15 μl reaction volume containing 1,5 μl of diluted cDNA, 7,5 μl of 
SSoAdvanced SYBR Green Supermix (BIO-RAD) and 1,5 μl of 10x Map1lc3b QuantiTect 
Primer Assay (Qiagen). Quantitative real-time PCR was performed in a iQ5 Optical System 
Software, which was initiated with enzyme activation by heating at 95 ºC during 30 sec, 
followed by 45 cycles of two steps, first step of 7 sec at 95ºC, second step of 15 sec at 55ºC.  
The melting step was performed with slow heating, starting at 65 ºC and with a rate of 0.5 ºC 
per 10sec, up to 95 ºC. A melting curve was always built to demonstrate a single amplification 
product reaction per well. 
The assay included a non-template control and a standard curve of cDNA. The amplification 
rate for each target was evaluated from the cycle threshold (Ct) numbers obtained with cDNA 
dilutions. 
2.4.4. Data Analysis 
Data analysis was performed by iQ5 Optical System Software for real-time PCR expression 
profile. To each gene, and each experiment, a standard curve was performed for assessing the 
efficiency of each set of primers. The reaction efficiencies were between 90% and 110%, and 
r
2
> 0.99, thus allowing the use of the comparative method for messenger RNA (mRNA) level 
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quantification, according to the following formula: 2
-ΔΔCt
x100 (Livak and Schmittgen, 2001). As 
reference gene were used hprt gene (Hprt QuantiTect Primer Assay, Qiagen). Statistical analysis 
was performed by the one-way ANOVA and student t-test. Data are represented as mean ± 
SEM. 
2.5.  Imunochemical procedures 
2.5.1. Free-floating Immunohistochemistry 
Free-floating  immunochemistry was initiated incubating brain sections on phenylhidrazine 
diluted in Phosphate buffered saline (PBS) (1:1000; 30min, 37°C) for peroxidase inhibition, 
followed by three washes with PBS (5’; 5’; 10’). The sections were blocked 1h at room 
temperature in PBS 0.1% Triton solution with 10% NGS and incubated with the primary 
antibodies diluted in blocking solution: mouse monoclonal anti-ataxin-3 (1H9, Chemicon, 
Temecula, CA, USA; 1:5000, overnight 4°C) and rabbit polyclonal anti-DARPP-32 
(Chemicon,Temecula, CA, USA; 1:2000, overnight 4°C). After the overnight incubation, the 
sections were washed three times with PBS. For light imaging, the secondary antibody used was 
biotinylated and followed a reaction with the vectastain elite avidin-biotin-peroxidase kit and by 
3,3’-diaminobenzidine substrate (both from Vector Laboratories, Burlingame, CA). 
 
2.5.2. Immunohistochemistry quantitative analysis 
The quantification of ataxin-3 positive inclusions was performed by scanning 8–10 coronal 
sections spread over the anterior-posterior extent of the striatum (inter-section distance: 200 
μm), using a 20× objective on Axioscope 2 Plus upright microscope (Zeiss, Jena, Germany). For 
each animal, the absolute number of inclusions in the striatum was calculated as described 
elsewhere (Alves et al., 2008a), using an image analysis software (ImageJ, National Institute of 
Health, USA). For the quantification of dopamine and cyclic AMP-regulated phosphoprotein, 
relative molecular mass 32,000 (DARPP-32) depletion volume, scanning of 8–10 coronal 
sections spread over the anterior-posterior extent of the striatum (inter-section distance: 200 
μm), using a 20× objective on Axioscope 2 Plus upright microscope (Zeiss, Jena, Germany). 
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and the same image analysis software (ImageJ, National Institute of Health, USA). The volume 
was estimated as described elsewhere (Alves et al., 2008a) and data were expressed as the 
evaluated DARPP-32 depleted volume (mm
3
). 
 
2.5.3. Immunocitochemistry of N2a  
Cells expressing EGFP-LC3 and mutant ataxin-3 were washed with PBS. The sections were 
counterstained with DAPI, washed three times and mounted with Fluorsave (Calbiochem, 
Germany). Light images were acquired with confocal microscope (LSM 510 Meta/Zeiss). 
 
2.6. Protein extraction and Western blot 
For the protein extraction protocol, brain tissue and cells were lysed in RIPA buffer solution 
(50 mM Tris HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) 
containing proteases inhibitors (Roche diagnostics GmbH, Mannheim, Germany) followed by a 
4s ultra-sound chase (1pulse/s). Pprotein concentration was determined using the Bradford 
protein assay (BioRad, Munich, Germany). Depending on the analysis, twenty (Neuro-2a), 
thirty (striatal primary cells) and sixty micrograms of protein extract were resolved in SDS-
polyacrylamide gels (4% stacking, 12% running; 20-80%) with exception of striatal primary 
cells analysis that were resolved in different SDS-polyacrylamide gels (4% stacking, 6% 
running; 50-50%).  The proteins were transferred onto PVDF membranes (GE Healthcare, 
Amersham, UK) according to standards protocols. The membranes were blocked by incubation 
in 5% nonfat milk powder in 0.1% Tween 20 in Trisbuffered saline (TBS-T) for 1 h at room 
temperature, and then incubated overnight with the following primary antibodies diluted in 
blocking buffer: anti-ataxin 3 (1H9; 1:5000; Chemicon, Temecula, CA, USA); LC3b (1:1000; 
Cell signaling, MA, USA); β-actin (1:10000; SIGMA); β-tubulin (1:10000; SIGMA). Blots 
were washed three times in TBS-T, for 15min each, and incubated with the secondary antibody 
goat anti-mouse (1:10 000; Vector Laboratories, Burlingame, CA) for 2h at room temperature. 
After washing, bands were visualized with Enhanced Chemifluorescent substract (ECF) (GE 
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Healthcare, Amersham, UK) and chemifluorescence imaging (Versadoc Imaging System Model 
3000, Bio-Rad, Munich, Germany. Semi quantitative analysis was carried out based on the 
optical density (OD) of scanned films (Quantity One 1-D image analysis software version 4.4; 
Biorad, Hercules, CA, USA). Specific ODs were normalized with respect to those for actin or 
tubulin for experiments on total homogenates. The specific OD was then normalized with 
respect to the amount of actin or tubulin loaded in the corresponding lane of the same gel. A 
partition ratio was calculated and expressed as a percentage. The western blotting analyses were 
performed in triplicate for each experimental set. 
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3.1. Carbamazepine increases autophagosome formation in N2a 
cells 
 
Mood stabilizing drugs, such as CBZ, have been associated to an increase of autophagy by 
an mTor independent pathway (Sarkar et al., 2007) Therefore, these drugs could play an 
important role in the clearance of misfolded proteins, which are at the origin of several 
neurodegenerative diseases. 
We first investigated whether CBZ would increase the autophagic flux in cellular models of 
MJD. Mouse neuroblastoma N2a cell lines stably expressing ataxin-3 MUT and EGFP-LC3 
were generated by infection with lentiviral vectors. These lines allow the observation of 
autophagosome formation after treatment with CBZ as compared with untreated cells 
(Fig.3.1A). Increased EGFP-LC3 puncta formation was observed in cells treated with CBZ, a 
profile that was similar to the one observed in cells treated with rapamycin, used as positive 
control. Using of a lysosomotropic reagent, chloroquine, which blocks degradation of LC3-II 
and allows enhanced detection of the amount of LC3 that is delivered to lysosomes for 
degradation (Mizushima and Yoshimori, 2007; Klionsky et al., 2008; Rubinsztein et al., 2009), 
leads to the clear detection of autophagosomes.  
To investigate whether the autophagosome formation observed by immunocytochemistry 
would correspond to autophagy activation¸ we performed western blot experiments to evaluate 
LC3 protein levels (Fig.3.1B-C) and mRNA expression (Fig.3.1D). Significant increase both in 
LC3II/LC3I ratio and in LC3 mRNA expression were observed in cells treated with CBZ when 
compared with controls (P<0.05). We also found high levels of LC3-II even under normal 
conditions (Fig.3.1B-C). Due to the highly sensitive nature of LC3 conversion and turnover 
assay, a high flux can be detected even during basal conditions, which makes it difficult to 
detect additional changes in LC3 turnover upon autophagy upregulation and for that to obtain 
meaningful results. Probably this explains the non-significant results of LC3-II/LC3I protein 
levels in rapamycin conditions (Fig.3.1C). Therefore, other assays should be performed in order 
to measure the autophagic flux. 
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Figure 3.1. Carbamazepine increases autophagosome formation in N2a cells. (A) Confocal 
microscopy analysis of cells expressing EGFP-LC3 and mutant ataxin-3. Carbamazepine increases 
the number of EGFP-LC3 puncta formation an effect that is apparent under chloroquine effect. Scale 
bar: 10µm (B-C) Western blotting analysis of Atx3MUT cell lysates. (B) Representative western 
blot probed for LC3. Note the presence of LC3II (MW: 14KDa) and LC3I (MW: 17KDa) (C) 
Optical densitometry analysis. The conversion of LC3I to LC3II is significantly higher in cells 
treated with 50µm of CBZ, as compared with the control. (D) Quantitative real-time PCR analysis 
of N2a cells expressing mutant ataxin-3. Relative mRNA expression of LC3 is significantly higher 
in cells treated with CBZ, comparative with the control. Values are expressed as mean ± SEM of 3 
independent experiments. *P<0.05 (One-Way Anova test, Bonferroni post-test).  
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3.2. Carbamazepine promotes clearance of aggregated and soluble 
mutant Atx3 in N2a cells 
Having found evidences of CBZ-mediated activation of autophagy, we then evaluated 
whether this effect would reduce the levels of mutant ataxin-3 in this cellular model of disease. 
Therefore, we performed a dose-response curve with different concentrations of CBZ in order to 
identify the optimal range of concentrations that would promote decrease of the misfolded 
protein. Again, rapamycin was used as positive control (Fig.3.2). A robust around 50% decrease 
in the levels of aggregates for the tested concentrations of CBZ, suggesting that CBZ mediated 
an important effect in the clearance of mutant ataxin-3, being 50µM of CBZ the concentration 
that led to the most significant decrease of aggregate and soluble mutant ataxin-3 (P<0.01; 
Fig.3.2 B-C). 
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In the same experiment, it was evaluated if the tested concentrations of CBZ could affect the 
cell viability. Using the resazurin assay, it was verified that the tested concentrations of CBZ 
were not toxic to cells, suggesting that the observed effects were not due to modification of cell 
viability (Fig.3.3) 
 
 
 
 
 
Figure 3.3. Cell viability analysis using the resazurin assay. CBZ treatment within 
the tested concentrations had no effect in cell viability. 
 
 
 
 
  
Figure 3.2 Carbamazepine promotes clearance of aggregated and soluble mutant Atx3 in N2a cells. 
(A-B) Western blotting analysis of Atx3MUT cell lysates. (A) Representative Western Blot probed to 
ataxin-3 and tubulin. Note the presence of endogenous Atx3 (MW: 42kDa); Atx3 MUT (MW: 67kDa); 
tubulin (MW: 55kDa) and aggregates (MW: 250kDa). (B) Optical densitometry analysis for ataxin-3 
aggregates. (C) Optical densitometry analysis for Atx3 MUT. Significant decrease of atx3MUT and 
aggregates was detected in cells treated with CBZ especially with for the 30-50µM concentration of CBZ. 
Each Atx3 lane was normalized according to the tubulin loading control band. Results were expressed as 
ratio Ataxin-3/Tubulin. Values are expressed as mean ± SEM of 3-6 independent experiments. *P< 0.05; 
**P<0.01 (One-Way Anova test). 
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3.3. CBZ treatment alleviates neuropathology in a lentiviral-based 
mouse model of MJD  
  
To investigate the effect of CBZ in vivo we generated a lentiviral MJD model (Alves et al., 
2008), where mice expressing At3MUT (72CAG) were treated during 3 weeks with 
200mg/kg/day of CBZ by gavage and after this time sacrificed and the brains processed for 
imunohistochemical analysis. 
Since Machado-Joseph disease is characterized by the presence of mutant ataxin-3 nuclear 
inclusions (Paulson et al., 1997), we investigated whether CBZ would clear mutant ataxin-3 
aggregates formed in this model. Staining with the 1H9 antibody revealed a significant decrease 
in the relative number of atx3MUT inclusions in CBZ treated animals, as compared to control 
mice (n=5, P<0.001; Fig.3.4 B-C).  
We further investigated whether neuroprotective effects accompanied the clearance of 
ataxin-3 inclusions. Given that expression of mutant ataxin-3 produces a depletion of neuronal 
DARPP-32 marker (Alves et al., 2008), we performed immunohistochemical staining and 
quantitative analysis of the tissue volume depleted of DARPP-32 immunoreactivity (Fig.3.4 D). 
A decrease of the DARPP-32 depleted volume in CBZ-treated mice compared to the control 
group was observed (n=5; Fig.3.4 E), that despite not reaching significance (p=0.0738), was 
suggestive that CBZ might reduce neuronal dysfunction mediated by mutant ataxin-3. 
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Figure 3.4. Lentiviral-based MJD mice model treated with CBZ presents an improvement of 
neuropathology. (A-E) Schematic representation and analysis of lentiviral-based MJD mice model treated 
during 3 weeks with 200 mg/Kg/day of CBZ. (A) Schematic representation of stereotaxic injection of 
lentiviral vectors in mice striata.  Lentiviral vectors encoding human mutant ataxin-3 with 72 glutamines 
(Atx3 MUT) were injected in the striata of 3 weeks old C57/Bl6 mice. (B-E) Immunohistochemical 
analysis of mice striatal sections. (B) Immunohistochemical staining for ataxin-3-positive inclusions. (C) 
Quantification of relative number of mutant ataxin-3-positive inclusions. Significant decrease of relative 
number of atx3 inclusions were detected in treated mice comparative with control group. (D) 
Immunohistochemical staining for the neuronal marker, dopamine- and cyclic AMP-regulated 
phosphoprotein of 32 kDa (DARPP-32). (E) Quantification of relative DARPP-32 depleted volume 
(%mm
3
). A decrease of relative DARPP-32 depleted volume (%mm3) was detected in treated mice as 
compared to control group. Values are expressed as mean ± SEM. **P<0.01 (paired Student’s t-test) of 
n=5 for each experimental set. Scale bar: 200µm. 
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3.4. Carbamazepine promotes clearance of aggregated and soluble 
mutant Atx3 in transgenic mice, by enhancing autophagy 
 
To further investigate the protective effects of CBZ at neuropathological and motor 
behaviour levels, at an advanced stage of disease, we then used a transgenic MJD mouse model, 
which expresses a truncated fragment of mutant ataxin-3 transcript with 69 glutamines 
(Torashima et al., 2008). First we performed a treatment of one week of a daily dose of 250 
mg/kg/day by gavage for biochemical analysis of brain homogenates. The lysates of the 
cerebellum were analyzed by western blot for the HA tag present in the transgenic mutant 
ataxin-3 (Fig.3.5 A). Robust and significant decreases in both aggregated protein (n=4, P<0.01; 
Fig.3.5 B) and soluble protein levels were observed (n=4, P<0.05; Fig.3.5 C) after one week of 
treatment when compared with the control group.  
In order to evaluate carbamazepine-mediated activation of autophagy we then analyzed the 
mRNA expression of LC3 by quantitive-real time PCR. A significant increase of mRNA 
expression of this autophagy protein marker was observed in treated mice as compared to the 
control group (n=6, P<0.001; Fig.3.5 D). 
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3.5. Motor behaviour of transgenic mice treated with CBZ  
 
We next evaluated the long-term effect of CBZ in behavioral performance of transgenic 
mice. While in the lentiviral model we evaluated the neuroprotective role of CBZ, since CBZ 
treatment was initiated one day after the injection of lentivirus, the study in this transgenic 
model allowed an evaluation of the disease rescue because the CBZ treatment was initiated 
when mice already presented a profound cerebellar atrophy and severe motor deficits.  
CBZ administration was initiated at 3 weeks of age with a daily dose of 250 mg/kg in the 
drinking water, during 12 weeks. Every two weeks behavioural assessment was performed. In 
the rotarod test, mice were forced to walk on a rotarod apparatus accelerating from 4 to 40 rpm 
in 5 minutes and on a constant speed rotarod. In both tests a tendency for improvement of 
performance of treated mice was observed over time (Fig.3.6 A-B).  
In the activity box, despite not reaching significance, robust differences were observed at the 
10 and 12 weeks time-points between the treated and control groups (Fig.3.6 C). Transgenic 
mice treated with CBZ travelled higher distances (Fig. 3.6 D), spending less time resting 
(Fig.3.6 E) and more time moving fast (Fig.3.6 F). 
Figure 3.5. Carbamazepine promotes clearance of aggregated and soluble mutant Atx3 in 
transgenic mice, by enhancing autophagy (A-C) Cerebellum lysates western blotting of transgenic 
mice treated during one week with 250 mg/kg/day of CBZ. (A) Representative Western Blot probed to 
HA tag of transgenic mutant ataxin-3 and tubulin. Note the presence of truncated ataxin-3 detected 
with the HA antibody (MW: 40kDa); aggregates (MW: <250kDa) and tubulin (MW: 55kDa). (B) 
Optical densitometry analysis for aggregate levels. (C) Optical densitometry analysis for HA levels. 
Significant decrease of HA and aggregates levels was detected in transgenic mice treated comparative 
to control group. Each Atx3 lane was normalized  according to the tubulin band. Tubulin was used as a 
loading control. Results were expressed as ratio HA/ Tubulin (n=4 for each experimental set). Values 
are expressed as mean ± SEM. *P< 0.05; **P<0.01 (Student’s t-test). (D) Quantitive real-time analysis  
of cerebellum lysates. Relative of mRNA expression of LC3 is significantly higher in transgenic mice 
treated with CBZ, comparative with the control group. Values are expressed as mean ± SEM of n=6 
for each experimental set. ***P<0.001 (Student’s t-test).  
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Figure 3.6. Transgenic mice treated with CBZ present improved motor performance. (A-F) 
Behavioral assessment of transgenic mice treated during 12 weeks with 250mg/Kg/day of CBZ (A-B) 
Rotarod test. (A) Mice were forced to walk on constant speed rotarod at 5rpm.  (B) Mice were forced 
to walk on a rotarod apparatus accelerating from 4 to 40 rpm in 5 minutes. Latency to fall was measured 
for each time point. (C-F) Activity box analysis of Tg model treated with CBZ. (C) Activity profile of 
the distance travelled by mice during the 40 minutes of analysis. (D-F) Analysis of the last 30 minutes, 
which assesses the mice general activity. (D) Distance travelled by mice. Tg mice treated with CBZ 
travel longer distance compared with the control group. (E) Time spent resting (no movement). CBZ 
mediated a decrease in the time spent resting of Tg mice relative to the control group. (F) Time spending 
moving fast. CBZ promoted and increase in the time moving fast relative to control group. n=4-5 for 
each experimental set.  
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In this work we explored a novel therapeutic approach to treat Machado Joseph disease by 
using a potential autophagy enhancer, CBZ. In accordance with previous reports that mood 
stabilizing drugs act in a m-Tor independent way to activate autophagy (Sarkar and Rubinsztein, 
2006), we provide the first in vivo evidence that CBZ increases autophagy and thereby promotes 
the clearance of soluble and aggregated mutant ataxin-3 in three models of MJD. Thus, these 
results should be further explored as a possible therapeutic approach to MJD. 
Increasing evidence reported in the last years, underline the importance of autophagy in the 
degradation of misfolded proteins causative of several human diseases (Ravikumar et al., 2002; 
Menzies et al., 2006; Pickford et al., 2008), Furthermore, the impairment of this mechanism is 
associated development of a neurologicaly-impaired phenotype or with the aggravation of 
pathology (Hara et al., 2006; Khan et al., 2008), which makes of autophagy a potential 
therapeutic target to attenuate neurodegenerative diseases such as AD, PD, ALS, MJD and HD 
(Webb et al., 2003; Ravikumar et al., 2004; Berger et al., 2006; Nascimento-Ferreira et al., 
2011; Zhang et al., 2011; Schaeffer et al., 2012). Many studies have been developed to identify 
molecules with the ability to activate autophagy through different pathways, being rapamycin 
the first effective treatment in activating autophagy by inhibiting mTor (Zhang et al., 2007; 
Williams et al., 2008). In a MJD transgenic mouse model, the beneficial effect of a rapamycin 
ester (cell cycle inhibitor-779, temsirolimus) was demonstrated, by improving its motor 
performance (Menzies et al., 2010). Nevertheless, as the mTOR pathway integrates diverse 
signals to regulate protein translation and cell growth, proliferation, and survival (Wullschleger 
et al., 2006), its permanent inhibition could lead to severe side effects. Moreover rapamycin is 
an effective immunosuppressant (Cruzado, 2008), which may cause undesirable effects for 
long-term treatment. Growing evidence points to an important role of mTor-independent 
pathways for autophagy activation. Accordingly, our group recently showed that lentiviral-
mediated overexpression of beclin-1, an m-TOR-independent autophagy activator, alleviates 
MJD neuropathology (Nascimento-Ferreira et al 2011). Nevertheless the approach involved 
viral gene transfer and may therefore take long to reach the clinics. An alternative could be the 
use of approved low-molecular weight drugs known to activate the autophagy pathway. Mood-
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stabilizing drugs such as valproic acid (VPA), carbamazepine (CBZ) and lithium (Li) have been 
associated to the induction of autophagy in glioma cells (Fu et al., 2010); hepatic fibrosis 
(Hidvegi et al., 2010), HD (Sarkar et al., 2005), and AD (Gomez-Sintes and Lucas, 2010), 
among others. Following these evidences, from a list of drugs that enhance autophagic 
degradation of misfolded proteins with polyglutamine repeats, we selected CBZ for this study 
because of its extensive safety profile in humans and its ability to cross the blood-brain-barrier. 
In the first part of this study we minitore EGFP-LC3 puncta formation, LC3 turnover, and 
mRNA expression of LC3. Previously, other pharmacological agents with ability to activate 
autophagy have been identified based on a GFP-LC3 transfected cell-based screen (Zhang et al., 
2007). Furthermore, this GFP-LC3 labeling method has been successfully applied to in vivo 
mammalian autophagy research, by generating transgenic GFP-LC3 transgenic mice 
(Mizushima et al., 2004), also in model organisms, including Drosophila (Rusten et al., 2004; 
Scott et al., 2004), nematodes (Melendez et al., 2003), plants (Yoshimoto et al., 2004) and 
zebrafish (He et al., 2009). In neuroblastoma cells overexpressing mutant ataxin-3 we observed 
that CBZ mediated the activation of autophagy. An increased EGFP-LC3 puncta formation, 
representing autophagosomes, was observed in cells treated with CBZ comparatively to control 
conditions (Fig.3.1 A). 
The activation of autophagy mediated by CBZ was confirmed using western blot assay 
(Fig.3.1 B-C) and by real-time PCR (Fig.3.1 D) that also showed increased levels of LC3. These 
results clearly indicate that autophagy flux is increased upon CBZ treatment comparatively to 
control conditions and are concordant with a previous study using CBZ to treat hepatic fibrosis, 
suggesting that CBZ plays an important role in autophagy enhancement (Hidvegi et al., 2010). 
As a consequence of the activation of autophagy, clearance of soluble and aggregated mutant 
ataxin-3 was observed in neuroblastoma MJD model, consistent with data obtained in other 
studies (Hidvegi et al., 2010; Nascimento-Ferreira et al., 2011). In order to identify the best 
condition to promote degradation of mutant protein different concentrations of CBZ were 
evaluated (Hidvegi et al., 2010; Xiong et al., 2011). Interestingly, even the lowest concentration 
of CBZ was able to promote extensive decrease of mutant ataxin-3 aggregates and soluble 
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protein levels, suggesting that lower concentrations of CBZ, regarding those previously 
described, could activate the autophagy pathway and lead to the clearance of mutant protein 
with similar efficacy. However, the efficiency of this process should be evaluated for longer 
times of treatment. As none of the tested concentrations affected cell viability, we chose to use 
50µM to the following experiments, since it promoted the most efficient reduction of mutant 
ataxin-3 levels.  
In the second part of this study we observed a neuroprotective effect of CBZ in the lentiviral-
based MJD mouse model. In the last years, lentiviral vectors have been used successfully to 
create in vivo models of disease by overexpression of mutant proteins involved in the 
corresponding pathologies, either in the striatum, substantia nigra, amygdala or cortex (de 
Almeida et al., 2002; Lo Bianco et al., 2002; Kirik et al., 2003; Lauwers et al., 2003; Alves et 
al., 2008). Lentiviral-mediated expression of mutant ataxin-3 in the rodent brain induces 
behavioral and neuropathological abnormalities associated with MJD, which may help to 
elucidate the molecular mechanism of mutant ataxin-3 toxicity and facilitate the evaluation of 
new therapeutic strategies (Alves et al., 2008; 2010; Nascimento-Ferreira et al 2011; Simoes et 
al., 2012). Animals injected with lentiviral vectors encoding for atx3MUT in the striatum, were 
submitted to the treatment with CBZ during 3 weeks. The duration and dose were similar to the 
previously described regimen for in vivo treatment of hepatic fibrosis (Hidvegi et al., 2010). 
This study provides evidence that simultaneous induction of MJD and stimulation of autophagy 
through CBZ treatment was able to hamper the disease progression in the lentiviral model of 
MJD, indicated by the decreased of the number ataxin-3MUT inclusions and the reduced 
neuronal dysfunction evaluated on darpp-32 stained sections, compared to control mice. This is 
concordant with the results obtained in the same MJD model when autophagy was promoted by 
overexpression of beclin-1 (Nascimento-Ferreira et al., 2011), indicating that autophagy has a 
main role in the clearance of ataxin-3MUT in this model of MJD. Therefore, these data suggest 
a possible neuroprotective effect mediated by CBZ, preventing the pathological symptoms when 
initiated at an early stage of the disease. Furthermore, as polyglutamine inclusions are not 
removed by proteasome function, which may even become progressively impaired upon the 
DISCUSSION 
53 
 
disease (Bence et al., 2001; Venkatraman et al., 2004), autophagy should be responsible for the 
ability of cells to clear the mutant protein and to retard the pathology. 
To further investigate whether CBZ would alleviate neuropathology and motor behaviour 
impairments associated to MJD, when treatment was initiated after the disease phenotype 
became apparent, we used a transgenic mouse model of MJD (Torashima et al., 2008) This 
transgenic mouse model has a predominant expression of mutant ataxin-3 in the cerebellum, 
which in MJD patients is one of the most affected regions (Rosenberg, 1992; Sudarsky and 
Coutinho, 1995; Durr et al., 1996; Rub et al., 2006; Alves et al., 2008). The L7 promoter that 
drives expression of the C-terminal mutant ataxin-3 transgene is associated with expression in 
Purkinje cells. Even though MJD neuropathology has been associated with preferential 
degeneration of the deep cerebellar nuclei there are growing evidences that Purkinje cells are a 
type of cells that are affected in MJD patients (Munoz et al., 2002; Scherzed et al., 2012), which 
confers physiological relevance to the model.  
Severe cerebellar atrophy and ataxic phenotype were already present at the time of initiation 
of CBZ treatment at three weeks of age. Nevertheless, CBZ led to rescue of the pathology, 
mediating a significant decrease in aggregated and soluble mutant ataxin-3 content within a 
short period of treatment, and attenuation of the phenotype upon longer term administration. 
This marked reduction in soluble and aggregated mutant ataxin-3 in the cerebellum is 
concordant with the results obtained regarding the clearance of antitrypsin Z in the liver of a 
transgenic model of hepatic fibrosis upon CBZ treatment (Hidvegi et al., 2010). The capacity to 
enhance degradation of both insoluble and soluble ataxin-3 may represent an important 
characteristic of CBZ as a potential therapeutic drug. 
The motor behavior assessment when using the rotarod was not conclusive, however the 
activity box tests revealed a modest but consistent tendency in the improvement of transgenic 
mice performance. The observed small but non-significant tendency for improvement in the 
rotarod performance could be explained by a) the short period of treatment, which may not have 
been sufficient to maximize the therapeutic effects in this severe model of disease, and b) the 
variability and reduced number of animals, which was aggravated by the use of animals of both 
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genders. Nevertheless, a clear tendency for an improved activity profile was observed in CBZ 
treated mice when compared to the controls at the 10 and 12 weeks time-points. Treated mice 
travelled longer distances, spent less time resting and more time moving fast. These results are 
in accordance with the hypoactivity reported for severe or late-stage disease models (Goti et al., 
2004; Bichelmeier et al., 2007; Boy et al., 2010), and are expected to arise from improvement 
of neuropathology. This could indicate that activation of autophagy pathway may delay the 
progression of the disease, even in an advanced stage of the pathology, evidencing that 
impairment of the autophagy pathway, of protein clearance and of neuronal dysfunction may not 
be irreversible. These results are in accordance with studies in SCA1, MJD and Huntington’s 
disease where it is shown that even in a late stage of the disease, the cells which preferentially 
degenerate in the disorder retain at least some ability to repair the damage caused by mutant 
ataxin-1 (Zu et al., 2004). 
Altogether, these data provide strong evidence that stimulation of autophagy by CBZ is able 
to prevent neuropathological and behavioral MJD-associated abnormalities when administered 
in an early stage and to partially rescue the pathological phenotype when administered in a late 
stage of the disease. Therefore, the results presented in this thesis suggest that the autophagy 
pathway plays an important role in the cellular degradation of mutant ataxin-3 and in the 
prevention of consequent pathology. Importantly, this work suggests that CBZ treatment could 
be explored as possible therapeutic strategy to MJD. 
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This work is a contribution to understand the potential of CBZ, a mood-stabilizing drug, in 
the mitigation of neurodegenerative disorders such as Machado-Joseph disease. Our results 
suggest that CBZ mediates activation of autophagy, degradation of mutant ataxin-3 and 
alleviation of MJD-associated neurophatology and motor behaviour, and should be further 
investigated for therapy of Machado-Joseph disease. 
CBZ is an autophagy-enhancing drug, which signals through the phosphoinositol pathway 
thereby up-regulating autophagy (Sarkar and Rubinsztein, 2006; Hidvegi et al., 2010). Previous 
work from our group indicated that activation of autophagy through an mTOR independent 
pathway might alleviate MJD (Nascimento-Ferreira et al 2011). Therefore we sought to 
investigate whether CBZ could be used as new non-invasive therapy for this severe disease for 
which no efficient treatment is available. Using an in vitro neuroblastoma model, and two in 
vivo models of MJD, we evaluated disease-modifying properties of CBZ. We provide in vitro 
and in vivo evidence that CBZ promotes activation of autophagy, reduction of mutant ataxin-3 
levels, and of MJD-associated neurophatology and motor behaviour.  
Overall, this study suggests that activation of autophagy by treatment with CBZ may be a 
promising therapeutic approach to MJD. Furthermore, combination of CBZ with other 
strategies, as previously reported in HD with combination of lithium and rapamycin (Sarkar et 
al., 2008) may also be beneficial. More studies with longer times of treatment, and more 
animals will need to be done, to assess the real impact of this drug in the clearance of mutant 
protein and alleviation of MJD, and in order to develop an effective therapeutic for this 
incapacitating disease.  
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